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Abstract
Hepatitis C virus (HCV) is a major cause of hepatitis and hepatocellular carcinoma (HCC) world-wide. Most HCV patients have
relatively stable disease, but approximately 25% have progressive disease that often terminates in liver failure or HCC. HCV
is highly variable genetically, with seven genotypes and multiple subtypes per genotype. This variation affects HCV’s
sensitivity to antiviral therapy and has been implicated to contribute to differences in disease. We sequenced the complete
viral coding capacity for 107 HCV genotype 1 isolates to determine whether genetic variation between independent HCV
isolates is associated with the rate of disease progression or development of HCC. Consensus sequences were determined
by sequencing RT-PCR products from serum or plasma. Positions of amino acid conservation, amino acid diversity patterns,
selection pressures, and genome-wide patterns of amino acid covariance were assessed in context of the clinical
phenotypes. A few positions were found where the amino acid distributions or degree of positive selection differed
between in the HCC and cirrhotic sequences. All other assessments of viral genetic variation and HCC failed to yield
significant associations. Sequences from patients with slow disease progression were under a greater degree of positive
selection than sequences from rapid progressors, but all other analyses comparing HCV from rapid and slow disease
progressors were statistically insignificant. The failure to observe distinct sequence differences associated with disease
progression or HCC employing methods that previously revealed strong associations with the outcome of interferon a-
based therapy implies that variable ability of HCV to modulate interferon responses is not a dominant cause for differential
pathology among HCV patients. This lack of significant associations also implies that host and/or environmental factors are
the major causes of differential disease presentation in HCV patients.
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Introduction
Hepatitis C virus (HCV) is a Hepacivirus that infects
hepatocytes and some lymphocytes [1,2]. It chronically infects
about 120–170 million people world-wide, resulting in about
350,000 deaths annually [3,4]. Disease caused by HCV ranges
from asymptomatic infection to severe hepatitis, with most people
having some degree of ongoing liver damage [1,5]. Roughly 25%
of chronically infected individuals have progressive disease, where
liver pathology proceeds from hepatitis of gradually worsening
severity, to hepatic fibrosis, cirrhosis, and often to fatal liver failure
or hepatocellular carcinoma (HCC). The rate of progression along
this spectrum varies from a few years in exceptionally rapid
progressors to many decades in slow progressors, with relatively
slow disease progression being the norm. HCV-induced liver
disease is primarily caused by hepatic inflammation and anti-HCV
immune responses [6–8]. Direct cytopathic effects from viral
replication may contribute to disease, but they are believed to be
secondary to immune-mediated damage.
HCV’s ,9,600 nucleotide positive-polarity RNA genome
encodes a polyprotein of ,3100 amino acids that is cleaved into
10 mature proteins (Fig. 1). The genome is surrounded by a capsid
composed of the viral core protein, and the capsid is enclosed by a
lipid envelope containing the viral glycoproteins E1 and E2. The
non-structural proteins (P7-NS5B) replicate the viral RNA, and
virions are secreted from the cell non-cytolytically [9,10]. The
HCV genome is highly variable, with seven genotypes that are less
than 72% identical at the nucleotide level [11]. Within the
genotypes, subtypes with nucleotide identities of 75–86% may
occur. Individual isolates of a given subtype are typically ,92–
96% identical, and as HCV replicates as quasispecies, multiple
variants differing by up to a few percent exist within individual
patients. The viral 59 untranslated region, the core gene, and the
extreme 39 end of the genome are relatively well conserved, and
two hypervariable regions within the envelope proteins, the 39 end
of the NS5A gene, and parts of the 39 untranslated region are very
poorly conserved.
Until recently the standard treatment for chronic HCV
infection was pegylated interferon a (IFNa) plus ribavirin for 24
to 48 weeks, which resulted in clearance of the virus [sustained
viral response (SVR)] in 50–60% of genotype 1 patients [12,13]. In
2011, two inhibitors of the HCV NS3 protease, telaprevir and
boceprevir, were approved for use in conjunction with interferon a
in HCV genotype 1 patients that improved SVR rates to ,75%
[14,15]. A third inhibitor of the NS3 protease (simeprevir) and a
nucleoside analog that targets the NS5B RNA polymerase
(sofosbuvir) were approved in 2013 [16–18], increasing efficacy
of the triple-therapy combinations. However, stimulation of the
interferon response remains key to efficacy of the existing triple
therapies, and HCV treatment will remain dependent on
interferon a until sets of direct-acting drugs with sufficient efficacy
to eradicate the virus by themselves is approved, as is expected to
happen [19].
HCV’s genetic variation has a major impact on success of both
interferon a-based therapy and direct inhibitor-based treatments.
Telaprevir and boceprevir are approved exclusively for patients
infected with HCV genotype 1 [20], whereas simeprevir is
approved for use against both genotype 1 and 4 infections [16].
Most experimental direct-acting agents are also genotype-specific
[21,22]. Interferon plus ribavirin therapy clears genotype 1
infections much less well than genotype 2 and 3 infections
(,50% compared to .80%, respectively) [23,24]. We previously
found that high genetic variation in the consensus sequences of the
HCV core, NS3, and NS5A genes was tightly correlated with
failure of interferon a plus ribavirin therapy [25–27]. Importantly,
all three of these genes can counteract the type 1 interferon
response [28]. We interpreted this association to indicate that high
viral variability impairs the ability of HCV’s interferon-suppressive
proteins to counteract the heightened type 1 interferon responses
induced by therapy. We and others also found that ,10% of
HCV’s ,3000 amino acid positions covary with at least one other
position, and that these covariances link together into a genome-
wide network of covarying positions [27,29]. These networks are
different among HCV sequences from responders and non-
responders to interferon plus ribavirin therapy [27,30,31],
implying a coordinated role for sequence variation throughout
the viral genome in antagonizing interferon responses.
The impact of HCV genetic variation on viral pathology is less
clear. It is well accepted that genotype 3 causes steatosis more
frequently than the other HCV genotypes [32,33]. Furthermore,
HCV infection can elevate levels of the pro-inflammatory cytokine
IL8 [34] through activation of the IL8 promoter by core, NS4B,
and/or NS5A [35–37], and there is a direct correlation between
core sequence variation, ALT levels, and IL8 promoter activation
[38]. Other associations between HCV genetic variation and
pathology are less well accepted. Some studies found little evidence
for virulence differences between the major HCV genotypes
[39,40], but most studies found differences, such as genotype 1
being more virulent than genotype 2 [41,42]. Most studies have
found genotype 1b to be more virulent and more highly associated
with HCC than other genotypes [43–47]. However, these
associations have not been apparent in other studies [48,49],
and some of the higher virulence of 1b has been suggested to be
due to accidental selection bias in the patient populations [50].
Stronger evidence exists for a role of HCV genetic variation on
HCC development. Most genetic analyses of HCV in the context
of HCC have focused on the HCV core and NS5A genes. The
HCV core protein has been reported to promote cellular
transformation in tissue culture [51] and in some animal models
[52,53], and several studies have found an association between
variations in the core coding sequence and the likelihood of
Figure 1. HCV genome. The HCV genome contains 59 and 39 untranslated regions and a single, long open reading frame that encodes 10 proteins.
The mature viral proteins encoded within the open reading frame and their major functions are indicated. Reprinted from [25] under the creative
commons license.
doi:10.1371/journal.pone.0103748.g001
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developing HCC [54–58]. Akuta et. al identified two core amino
acid positions (70 and 91) where non-wild type residues were
significantly associated with HCC in genotype 1b patients [55–57].
Furthermore, Fishman et. al. examined core nucleotide positions
and their putative effect on known RNA structures in subtype 1b
and identified several positions where substitutions were associated
with increased risk of HCC [54]. Inhibition of PKR activity by the
NS5A PKR binding site has been shown to be needed for cellular
transformation and tumorigenicity in nude mice [59], but both
low [60,61] and high [62] diversity of the PKR binding site have
been associated with HCC. Studies in which HCV variation has
been described at just the subtype level found that 1b is associated
with a higher risk of HCC than 1a [46,47,63]. Three studies
examined full-length HCV genomes at the sequence level in the
context of HCC [64,65] [66], and each study identified a small
number of amino acid positions where genetic variation was
significantly associated with HCC.
We hypothesized that HCV genetic variation may be associated
with differential virulence in HCV, specifically with the rate of
advancement of liver disease and/or development of HCC. This
hypothesis was based on our identification of clear HCV genetic
patterns that were associated with outcome of interferon-based
antiviral therapy [25–27]. The null hypothesis was that environ-
mental and/or host-specific factors were dominant in determining
the differential disease outcomes. Two independent patient sets
were employed to assess this hypothesis. The first set was used to
evaluate association of HCV genetic variation with development
of HCC. These patients were identified through the Liver Cancer
Research Network (LCRN; [67]). The second set was used to
assess the role of HCV genetic diversity in the rate of disease
progression. These patients were derived from the untreated
observational control arm of the HALT-C clinical trial, which was
a multi-center, randomized controlled study designed to determine
if long-term interferon a treatment would ameliorate HCV’s
pathology [68]. Our strategy was to determine the consensus
sequence for the full HCV coding region by direct sequencing of
nested reverse-transcription-PCR products, and then to compare
HCV genetic patterns in HCC vs. non-HCC patients for the




This study was approved by the Saint Louis University
Biomedical Institutional Review Board (HCC cohort,
IRB#1570; HALT-C cohort IRB#14138). All participants pro-
vided written informed consent to participate in the parent HALT-
C and LCRN studies; this informed consent included granting
permission for use of de-identified samples for study-approved
ancillary studies such as this. This informed consent procedure was
approved by the IRBs for the parental study, and each patient’s
informed was documented and filed by the parental studies.
Sequencing the HCV open reading frame
HCV RNAs were isolated from patient serum and cDNAs were
synthesized as previously described [69,70]. For the HCC samples
and cirrhotic controls, cDNAs were sequenced with the nested
reverse transcriptase-PCR and direct sequencing methods we
previously employed for Virahep-C samples [26,69]. cDNAs from
the HALT-C samples were sent to the Broad Institute for nested
reverse transcriptase-PCR and direct sequencing of the overlap-
ping amplicons by the chain-termination method as described
[70]. Approximately 50% of the viral sequence data were obtained
by this approach. The remaining data for the HALT-C sequences
were obtained employing our higher-sensitivity nested reverse
transcriptase-PCR and direct sequencing methods [26,69]. The
extreme 39 end of the HCV open reading frame could not be
obtained for all patients. Consequently, the sequences were
truncated at aa 8991 for the cancer cohort and at aa 8994 for
the HALT-C patients to ensure equal coverage of all genomic
regions in the analyses. This eliminated the 14 C-terminal codons
for the cancer cohort and the 13 C-terminal codons for the
HALT-C sequences. Genbank numbers for HCV sequences from
the HCC cohort are: KC439481–KC439502 (HCC) and
KC439503–KC439527 (cirrhotic controls). Genbank numbers
for HCV sequences from the HALT-C patients are: JX463525–
JX463554 (time point 1, rapid progressors); JX463555–JX463584
(time point 1, slow progressors); JX463585–JX463612 (time point
2, rapid progressors), and JX463613–JX463641 (time point 2, slow
progressors). The list of sequence IDs, accession numbers and
experimental groups for both patient cohorts are in Table S1.
Clonal sequencing in the E2 gene
Twelve clones encompassing the amino-terminal region of the
E2 glycoprotein (aa 384–476 in the HCV polyprotein) that
included the hypervariable region 1 (aa 384–410) from each of six
HCC and six cirrhotic control patients were cloned for
quasispecies analyses. HCV RNAs were isolated and cDNA was
synthesized as was done for the direct sequencing. HCV sequences
were amplified by nested PCR from the cDNAs under high-fidelity
conditions employing the Hotstart HiFidelity Polymerase kit
(Qiagen). The PCR products were cloned and independent clones
were randomly selected for sequencing.
Sequence analyses
All analyses except dinucleotide frequency analyses and codon
selection biases were conducted at the amino acid level. Consensus
population-wide reference sequences were derived from 107 full-
length genotype 1b or 103 genotype 1a ORFs downloaded from
Genbank in January, 2012. Sequence alignments were done with
Muscle [71]. Positions that varied relative to the genotype 1a or 1b
reference consensus sequences were identified with the EMBOSS
program Infoalign 4501 [72]. Mean genetic distance was
calculated using the p-distance algorithm in the MEGA v.
5 DNA analysis package [73]. The codon selection analysis based
on the ratio of dN/dS substitutions was done using the single
likelihood ancestor counting (SLAC) method with the HKY85
substitution mode and a significant level of p,0.05 [74]. The
predicted frequency of specific dinucleotide pairs within an ORF
was calculated by multiplying the frequency in the ORF of both
bases in the pair by the length of the ORF using customized PERL
scripts. The observed base and dinucleotide compositions were
counted directly using customized PERL scripts.
Amino acid covariance analyses
All possible amino acid covariances within the HCV open
reading frame were determined employing the observed-minus
expected-squared algorithm with a 1% false discovery rate as we
have previously described [27,75]. Networks in the covariance
data were graphed employing Cytoscape [76]. Network metrics
were calculated employing the Network Analyzer plug-in for
Cytoscape [77].
Statistical analyses
Positions of skewed amino acid variance between the groups of
sequences were identified by comparing positions of variance in
HCV Genetic Variation and Pathology
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each group with a Mann-Whitney ranked sums test. Differences in
the average protein distances, the average number of variations/
sequence and dinucleotide frequencies were compared with a t-
test. Statistical analyses were carried out using SPSS v19 (IBM
Corporation, Armonk, NY). Baseline variables in the rapid and
slow progressor groups were compared using the chi-square test,
the t-test, or the Wilcoxon rank-sum test using SAS v.9.3 (SAS
Institute, Cary, NC).
Results
Patient selection and sequencing to evaluate association
of HCV genetic variation with HCC
Fifty patients were identified through the Liver Cancer
Research Network (LCRN) and Dr. Di Bisceglie’s practice at
Saint Louis University for the cancer cohort. All patients were
infected with HCV subtype 1b and had a clinical diagnosis of
cirrhosis at or prior to sample collection. Exclusion criteria
included co-infection with HBV or HIV, evidence of alcohol
abuse, and evidence of other liver diseases including non-alcoholic
fatty liver disease or hemochromatosis. ‘‘HCC patients’’ had a
definite or presumed HCC diagnosis at sample collection. Definite
HCC was biopsy-proven HCC or the presence of a new defect
within the liver noted on imaging studies with a serum alpha-
fetoprotein (AFP) level of .1,000 ng/ml. Presumed HCC was
three separate imaging techniques suggestive of HCC, a new
hepatic defect followed by massive hepatic involvement and death,
or a new hepatic defect with increasing size or increasing serum
AFP. ‘‘Cirrhotic controls’’ were cirrhotic (confirmed by liver
biopsy, with Metavir score $4) but had no clinical evidence of
HCC at the time of sample collection. HCC was excluded in the
controls by routine ultrasound surveillance every 6 to 12 months
according to the AASLD practice guideline on management of
HCC. The HCC and cirrhotic control patient groups were
matched by age and sex. The annual incidence rate of HCC in
cirrhotic HCV-infected patients is 1 to 4% [78]. Therefore, our
power calculations assumed that two of the 25 cirrhotic controls
(8%) that were cancer-free at sample collection would develop
HCC within a few years. Using 25 controls yielded .80% power
at a=0.05 to detect genetic differences similar to what we had
observed with the Virahep-C samples between the HCC and
cirrhotic groups, even with this high degree of contamination of
the controls.
Consensus sequences for the full HCV coding region were
obtained from serum-derived RNA employing the nested reverse
transcriptase-PCR and direct sequencing methods we previously
employed [26,69]. We were unable to sequence the full coding
region from three HCC patients so these sequences were excluded.
The HCC and cirrhotic control groups remained statistically
indistinguishable for age and sex following exclusion of these three
patients (Table 1).
HCV positional sequence differences associated with
HCC
To identify amino acid positions in the HCV sequence that
differed consistently between the HCC and cirrhotic control
sequences, we aligned the sequences and examined amino acid
distributions at all 2997 positions. The amino acid distributions at
25 aa positions were significantly different between the HCC and
cirrhotic control samples, with p-values ranging from 0.001 to
0.046 (Table 2). As a control to determine the frequency of chance
associations in this analysis, the 47 sequences were randomly re-
sorted into five sets of 25 and 22 sequences and positions where the
amino acid distribution differed significantly between these pairs of
biologically irrelevant groups were identified. We observed a mean
of 15.2 (10–22) positions that differed with a mean p-value of 0.025
(0.001 to 0.049) in these control comparisons. The larger number
of significantly different positions in the HCC versus cirrhotic case
compared to the scrambled control sequence sets suggests some of
the 25 positions of skewed variance between HCC and cirrhotic
controls may be associated with a biological difference between the
two groups. Four of the positions that were significantly associated
with HCC occurred in the very small (63 residue) p7 gene.
HCV consensus sequence diversity differences are not
associated with HCC
To determine if there were diversity differences between the
HCC and cirrhotic control sequences, pairwise genetic distances
between all samples within the HCC and cirrhotic controls groups
were calculated, and then the average pairwise distances were
compared between the two groups. The mean pairwise differences
for the HCC and cirrhotic control groups (0.081 vs. 0.080,
respectively) were not significantly different. A more sensitive
method to measure genetic diversity is to quantify the number of
variations relative to a population-wide consensus reference
sequence for each sample. Therefore, each sample was aligned
to a subtype 1b population-wide reference sequence, and the
number and identity of variations were recorded for each sample
as we have done before [25,26,79]. No significant differences were
found between the HCC and cirrhotic controls for either total
number of variations in the two groups or the number of variations
that were unique to either the HCC or cirrhotic groups. This held
true when the entire polyprotein was evaluated as a single unit and
when the viral genes were considered individually.
HCV quasispecies patterns in the E2 HVR region are not
strongly associated with HCC
To determine if there were genetic differences between the
HCC and cirrhotic groups at the quasispecies level, we sequenced
12 independent clones covering the 27 amino acid-long E2
hypervariable region (HVR) plus 66 amino acids downstream of
the HVR from each of six randomly-selected patients in both the
Table 1. Age and gender of patients from whom the HCC and cirrhotic samples were derived.
Cirrhotic control HCC P value1
Number of patients 25 22 –
Gender (M/F) 19/6 16/6 ns
Age (mean 6 SD) 57.469.6 61.768.2 ns
Age (range) 49–76 44–82 ns
1ns, non-significant.
doi:10.1371/journal.pone.0103748.t001
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HCC and cirrhotic groups. The number of amino acid differences
relative to a genotype 1b population reference per patient was not
significantly different between sequences from the HCC and
cirrhotic samples. Amino acid pairwise distances were determined
within the set of 12 sequences for each patient as a measure of the
quasispecies diversity. The mean pairwise protein genetic differ-
ences were slightly higher in the E2 region (0.066 vs. 0.036) and
the HVR region (0.278 vs. 0.148) for the HCC samples compared
to the cirrhotics. Sequence complexity within the 12 sequences per
patient was also assessed. The HCC patients had an average of 9.2
unique E2 sequences per patient compared to 7.2 for the cirrhotic
controls, and the HCC samples had an average of 7.5 unique
HVR sequences per patient compared to 6.5 for the cirrhotics.
Similar results were obtained when the data were analyzed at the
nucleotide level. Thus, the HCV sequences in the HCC patients
appeared to be slightly more diverse and complex than in the
cirrhotic controls, but these differences were not statistically
significant. There was no evidence of positive selection in these
sequences. Overall, no prominent differences in the quasispecies
spectra in the HCC and control patients were detected.
Selective pressures associated with HCC
We examined the HCC and cirrhotic control sequences for
differences in selective pressure at all 2997 codons using the SLAC
method with the HKY85 substitution mode in order to identify the
codons under positive or negative selection [74]. 825 of the 2997
codons were under negative selection and 12 codons were under
positive selection in the HCC sequences, while 900 codons were
under negative selection and 13 codons under positive selection in
the cirrhotic controls (Table 3). Only three of the positively-
selected codons were shared between the two groups.
To help evaluate whether these selective differences may be
associated with disease state or may simply represent selective
pressures on the HCV population as a whole, we randomly
sampled six sets of 22 or 25 HCV 1b coding sequences of the same
length (2997 codons) from Genbank and examined them for
codon selection differences. Six of the 25 positions under positive
selection in the HCC or cirrhotic control sequences were not
under positive selection in any of the six randomly selected
sequence sets (bold in Table 3). This indicates that the positive
selection pressures on most of the sites we identified were probably
unrelated to the patient’s disease state, but that selection at the six
codons unique to the HCC or cirrhotic patients may reflect
evolutionary pressures associated with these advanced disease
states.
UU and UA dinucleotide frequency differences are not
associated with HCC
RNase L is an endoribonuclease that cleaves RNA at single-
stranded UA and UU dinucleotides [80]. RNAse L contributes to
the innate immune responses against many viruses. We and others
have shown that RNase L exerts evolutionary pressure on HCV
genomes, as evidence by a reduced frequency of UU and UA
dinucleotides than would be expected by chance [26,81]. We
extended these analyses by determining the ratio of observed/
predicted dinucleotide frequencies for every possible dinucleotide
pair for each of the HCV sequences from the HCC and cirrhotic
patients. All of the samples showed the predicted reduced
frequency of UA and UU dinucleotide pairs, with an average
observed/expected ratio of 0.81 and 0.94 respectively. However,
there were no significant differences in the frequency of any
dinucleotide pair between HCC and the cirrhotic controls.
Amino acid covariance patterns associated with HCC
Next, we asked whether differences in genome-wide amino acid
covariance networks distinguished the HCC and cirrhotic control
sequences. This analysis was based on our previous detection of
prominent differences in the networks from responders and non-
responders to interferon-based therapy [27,31]. Amino acid
covariance networks were generated for the HCC and cirrhotic
controls as previously described [75]. As has been observed for
other HCV sequence sets [27,29,31,75], covariance networks
containing residue positions from all 10 proteins that had a hub-
and-spoke topology were observed. However, the HCC network
had many fewer nodes and was much less tightly connected than
the cirrhotic network (Table 4). The less-connected nature of the
HCC network was obvious visually, as it formed two major and
many smaller networks instead of a single large network as was
formed by the cirrhotic sequences (Fig. 2).
We previously found that detection of covariances was sensitive
to the number of sequences employed, with 22–25 sequences
being on the lower end of the useful range [75]. Therefore we
asked if this network integrity difference was due to the fewer
number of sequences in the HCC set by randomly selecting six sets
of 22 cirrhotic sequences and generating analogous amino acid
covariance networks. All of the networks contained very similar
numbers of nodes and covarying pairs as were found in the
network with 25 cirrhotic sequences, suggesting that the network is
robust to the loss of a few sequences (Table 4). To test the
possibility that the network connectivity differences were due to a
Table 2. Positions where the distribution of amino acids
differ in HCC and cirrhotic control sequences.
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random sampling of HCC sequences, we generated analogous
covariance networks from two other sets of full-length HCV
sequences from HCC-positive patients [64,65] (15 or 13 sequenc-
es). We also combined these two sequence sets and generated two
networks from randomly selected sets of 22 sequences from the
combined set of 28 sequences; Table 4). In all 4 of these HCV
covariance networks derived from HCC patients outside of our
patient cohort, the covariances formed a single, highly connected
network with network parameters similar to the cirrhotic network
and to the previously published HCV networks [27,75]. This
suggests that the fragmented covariance network observed with
our HCC sequences is unlikely to be a general feature associated
with HCC patients.
Positional differences in the HCV core gene associated
with HCC
Genetic variations at 11 nucleotide [54] and two amino acid
[55–57] positions in the core gene have been associated with
HCC. Therefore, we evaluated these genetic signatures in our
sequences. The HCC and the cirrhotic control sequences both
predominantly carried the control-type rather than the HCC-type
sequences at 8 of the 11 sites that were associated with HCC by
Fishman et al. [54] (Table 5). Furthermore, the distribution of
HCC- and control-type sequences at all of these positions was
quite similar in our HCC and cirrhotic sequence sets. Sequence
data for four of these positions are available for an independent set
of cirrhotic patients [62]. The sequence patterns in this
independent cirrhotic cohort were nearly identical to the patterns
we observed at all 4 positions (Table 5).
Very similar results were obtained when we analyzed amino
acid variation at core residues 70 and 91 (these codons include
nucleotides 209 and 271, respectively). Having a residue other
than arginine at position 70 or leucine at position 91 has been
associated with HCC [55–57]. The majority of our HCC and
cirrhotic sequences had the cancer signature at both positions 70
and 91 (Table 5). These results were corroborated by the external
set of cirrhotic sequences. Therefore, the sequence patterns at all
11 nucleotide positions and both of the amino acid positions in
core that have been previously associated with HCC were
distributed almost identically among the HCC and cirrhotic
sequences, with non-cancer sequence patterns predominating at 8
of the 11 nucleotide positions.
Patient selection and sequencing to evaluate association
of HCV genetic variation with rate of disease progression
The HALT-C trial evaluated the efficacy of long-term low-dose
interferon a therapy on the rate of progression of liver disease in
HCV patients who had previously failed interferon plus ribavirin
therapy [68]. The study included a large observational control arm
that did receive long-term interferon therapy, and hence provides
a unique resource for studying HCV’s role in disease progression.
Sixty patients from the observational arm of the HALT-C study
who had been followed for four years were therefore identified for
analysis; 30 were ‘‘slow progressors’’ and 30 were ‘‘rapid
Table 3. Codons under positive selection in the HCC and cirrhotic control sequences.
Codon Gene Group dN-dS P value
75 Core Cirrhotic 2.341 0.039
384 E2 Cirrhotic 6.042 0.008
387 E2 Cirrhotic 3.455 0.039
397 E2 Cirrhotic 5.512 0.011
401 E2 Cirrhotic 5.514 0.011
476 E2 Cirrhotic 3.650 0.012
478 E2 Cirrhotic 4.741 0.021
479 E2 Cirrhotic 3.470 0.030
522 E2 Cirrhotic 4.359 0.005
1384 NS3 Cirrhotic 2.630 0.026
2278 NS5A Cirrhotic 2.632 0.026
2968 NS5B Cirrhotic 4.578 0.002
2983 NS5B Cirrhotic 2.804 0.015
387 E2 HCC 3.283 0.026
401 E2 HCC 4.197 0.004
407 E2 HCC 3.032 0.017
434 E2 HCC 3.795 0.013
461 E2 HCC 3.025 0.017
522 E2 HCC 2.811 0.036
837 NS2 HCC 3.289 0.044
962 NS2 HCC 3.617 0.020
1098 NS3 HCC 3.010 0.018
2632 NS5B HCC 3.983 0.009
2983 NS5B HCC 4.187 0.001
Bold indicates positions unique to the HCC or cirrhotic sequence alignments compared to alignments of randomly selected HCV control sequences.
doi:10.1371/journal.pone.0103748.t003
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progressors’’. All patients were infected with HCV subtype 1a, had
failed prior interferon a plus ribavirin therapy, and had Ishak
fibrosis scores at entry to HALT-C of 3 or 4. Patients co-infected
with HBV or HIV were excluded. Patients were defined as ‘‘Rapid
Progressors’’ if any of the standard HALT-C outcome criteria
were met during the observation period: having a Child-Turcotte-
Pugh (CTP) score $7 on two consecutive study visits, variceal
hemorrhage, ascites, bacterial peritonitis, encephalopathy, ad-
vancement of the Ishak fibrosis score $2 points compared to the
initial score, development of HCC, or dying from liver-related
causes. ‘‘Slow Progressors’’ were defined as patients who did not
meet any of these HALT-C outcomes during the observational
Table 4. Basic amino acid covariance network parameters for the HCC and cirrhotic sequences.




HCC 22 86 80 1.9 0.022
Cirrhotic 25 128 296 4.6 0.036
Randomly sampled sets of 22 cirrhotic sequences
Set 1 22 123 320 5.2 0.043
Set 2 22 120 255 4.2 0.036
Set 3 22 118 309 5.2 0.045
Set 4 22 121 327 5.4 0.045
Set 5 22 118 215 3.6 0.03
Set 6 22 112 160 2.8 0.03
External HCC sequence sets
Pooled set 1 22 116 505 8.7 0.76
Pooled set 2 22 138 663 9.6 0.07
Takahashi et al.1 15 88 441 10 0.12
Nagayama et al.2 13 99 195 3.9 0.04
1Sequences obtained from [65].
2Sequences obtained from [64].
doi:10.1371/journal.pone.0103748.t004
Figure 2. Amino acid covariance networks for the HCC and cirrhotic sequences. Amino acid covariances within alignments of the HCV
cirrhotic (left) and HCC (right) sequences were graphed with the covarying positions (nodes) represented as circles and the covariances between the
positions (edges) as lines. The size of the nodes is proportional to the number of edges that they contact. Yellow nodes are within structural proteins
and green nodes are in non-structural proteins. The amino acid residue position numbered relative to the HCV polyprotein is indicated in the larger
nodes.
doi:10.1371/journal.pone.0103748.g002
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period. The slow responders included 23 patients whose HCV
titers never became undetectable during failed interferon-based
antiviral therapy and 7 breakthrough or relapse patients. The
rapid responders included 28 poor responders and 2 break-
through/relapsers. The rapid and slow progressor groups were
statistically indistinguishable at assignment to the control arm of
HALT-C for an array of clinical parameters relevant to liver
disease (Table 6).
The HCV open reading frame was sequenced for each patient
from two time points separated by three years. Time point 1 (TP1)
was nine months into the HALT-C observational period to allow
HCV titers to rebound from failed interferon-based antiviral
therapy that all patients received prior to randomization into the
interventional or control arms of the study. The second time point
(TP2) was at the end of the 45 month observational period.
Consensus sequences for the HCV coding region were obtained
from serum-derived RNA by direct sequencing of overlapping
nested reverse transcriptase-PCR amplicons as previously de-
scribed [26,69,70]. We were unable to sequence the full coding
region from two rapid progressor and one slow progressor samples
for time point 2, so these sequences were excluded from analyses
involving time point 2.
HCV positional differences associated with rate of disease
progression
There were 15 positions in the TP1 and 13 positions in the TP2
sequences where the distributions of amino acids were significantly
different between rapid and slow progressors, with seven of those
positions overlapping between time points (Table 7). To help
evaluate the likelihood that these may be spurious associations, we
generated five sets of paired sequence groups where the 60
sequences were randomly assigned to one of two groups, with both
groups containing 30 sequences. The number of positions that
were significantly different between these pairs of randomized
sequence sets ranged from 14 to 25, with a mean of 16.6. P-values
ranged from 0.001 to 0.049, with a mean of 0.033. These values
were very similar to the values seen when the rapid and slow
progressor sequences were compared, suggesting that the differ-
ences in Table 7 are unlikely to reflect important biological
variations associated with rate of disease progression.
HCV consensus sequence diversity differences are not
associated with rate of disease progression
Pairwise genetic distances were calculated for the sequences in
the rapid and slow groups for both TP1 and TP2 as we did for the
cancer cohort. No significant differences were observed in the
average pairwise distances between the rapid and slow progressors
for either time point or between time points. Positions of variance
relative to a population-wide reference were identified for rapid
and slow progressors at both time points, and no significant
differences were found at either time point between the two
groups. This was true both when the entire polyprotein was
evaluated as a single unit and when the viral genes were
considered individually.
The paired sequences from TP1 and TP2 for each patient were
compared and the numbers of mutations at the protein level were
determined for each pair. There were no significant differences in
the number of mutations during the three years between TP1 and
TP2 between the rapid and slow progressors. This was true when
the full polyprotein, each individual gene, or just the hypervariable
regions 1 and 2 in E2 were compared.
Selective pressures associated with disease progression
The rapid and slow progressor sequences were examined for
codon selection differences using SLAC method as we did for the
cancer cohort. Far more codons were under negative selection
Table 5. Positions in core associated with HCC.
Residue identity Control-type/HCC-type residues (number of sequences)
Residue number1 Control-type HCC-type Cirrhotic sequences HCC sequences External cirrhotic sequences2
Nucleotide positions3
36 A G/C 25/0 21/1 22/5
78 U C 1/24 2/20 1/25
209 G A 7/18 5/17 6/19
271 U/C A 3/22 5/17 6/19
309 U C/A 21/4 17/5 na4
384 C U 25/0 22/0 na
408 C U 24/1 21/1 na
435 G A/C 25/0 22/0 na
465 C U 24/1 20/2 na
481 G A 25/0 21/1 na
546 G A/C 23/2 19/3 na
Amino acid positions5
70 R non-R 7/18 5/17 5/21
91 L M 3/22 5/17 6/19
1Numbered relative to the start of the polyprotein.
2Sequences obtained from [62].
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(,1100 in both groups) than were under positive selection at both
time points. The number of codons under positive selection was
higher for slow progressors compared to rapid progressors at both
time points (14 vs. 7 at TP1; 18 vs. 8 at TP2). Most of the codons
under positive selection for the rapid progressors overlapped with
those identified for the slow progressors (Table 8).
To help evaluate whether these differences in the number of
codons under selection may be related to the rate of disease
progression, we randomly selected six sets of 30 subtype 1a
sequences from Genbank and examined their positive selection
patterns. The number of sites under positive selection for the
control sets ranged from 8 to 22 with an average 15.5. All but
three of the codons for TP1 and seven of the codons for TP2 were
under positive selection in one or more of the control sets
(Table 8). Therefore, almost all of the sites under positive selection
in the HALT-C dataset were not preferentially associated with the
rate of disease progression. However, the slow progressor
sequences were under greater positive selection pressure compared
to the rapid progressor sequences.
UU and UA dinucleotide frequency differences are not
associated with rate of disease progression
The ratio of observed/predicted dinucleotide frequency was
determined for every possible dinucleotide pair for each sample as
before. As with the HCC cohort, all of the samples had reduced
frequencies of UA and UU dinucleotides, but there were no
significant differences in the observed/expected UU or UA ratios
between the rapid and slow progressors, either within a time point
or when the time points were combined. Only the AU
dinucleotide had a statistically significant difference in the
observed/predicted ratio between rapid (0.919) and slow (0.933)
progressors (p,0.001). Although this is statistically significant, the
magnitude of the change is very small and hence the difference
unlikely to be biologically significant.
Amino acid covariance patterns are not associated with
rate of disease progression
Finally, we generated amino acid covariance networks for the
HCV sequences from the rapid and slow progressors at both time
points using the same methods used for the HCC cohort. As has
been observed for other HCV sequence sets [27,29,31,75], amino
acid covariance networks were identified that involved residue
positions from all 10 proteins and that had a hub-and-spoke
topology. For both time points, network parameters including
number of nodes, number of edges, mean number of neighbors,
density and clustering coefficient were very similar between rapid
and slow progressors (Table 9). About half of the covarying residue
pairs and over 80% of the residue positions overlapped between
rapid and slow progressor networks, indicating that the networks
were very similar (data not shown). The networks generated at the
Table 6. Baseline characteristics of patients from whom the rapid and slow progressor samples were derived.
Slow progressors Rapid progressors P value1
Number of patients 30 30 –
Age (mean 6 SD) 49.566.0 47.665.9 ns2
Female sex (% of patients) 26.7 43.3 ns
Duration of exposure to HCV (yr) (mean 6 SD) 26.367.1 25.766.3 ns




Body-mass index (BMI) (mean 6 SD)4 28.665.2 31.867.6 ns
Diabetes (% of patients) 13.3 20.0 ns
Lifetime alcohol consumption (no. of drinks) (median) 8713 10516 ns5
Lifetime alcohol consumption (no. of drinks) (interquartile range) 2062–30286 1397–25913
Baseline serum HCV RNA (log10 IU/ml) (mean 6 SD) 6.560.4 6.560.5 ns
Serum alanine aminotransferase (ALT) (U/liter) (mean 6 SD) 82.8642.5 100.1656.9 ns
Ratio of the patient’s alanine aminotransferase (ALT) level to the upper limit of normal (ULN)
(mean 6 SD)
1.761.1 1.860.9 ns
Total serum bilirubin (mg/dl) (mean 6 SD) 0.760.3 0.860.5 ns
Serum albumin (g/dl) (mean 6 SD) 4.060.3 3.960.4 ns
Prothrombin time (INR) (mean 6 SD) 1.060.1 1.060.1 ns
Ishak fibrosis score6 (mean 6 SD) 3.160.6 3.160.6 ns
Ishak inflammation score7 (mean 6 SD) 7.762.0 7.561.8 ns
Esophageal varices (% of patients) 10.0 13.3 ns
1T-test or chi-square test unless otherwise indicated.
2Non-significant (p,0.05).
3Race or ethnic group was self-reported.
4BMI is the weight in kilograms divided by the square of the height in meters.
5Wilcoxon rank-sum test.
6The Ishak fibrosis score range is 0 (no fibrosis) to 6 (cirrhosis).
7The Ishak inflammation score range is 0 (best) to 18 (worst).
doi:10.1371/journal.pone.0103748.t006
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two time points for the rapid progressors were almost indistin-
guishable, as were the two networks for the slow progressors.
Therefore, covariance network analysis failed to identify differ-
ences between the rapid and slow progressor sequences.
Discussion
HCV is genetically very diverse, and viral genetic variation is a
major contributor to virulence in many viral pathogens. However,
evidence for or against HCV’s high genetic variation leading to
differential virulence within a genotype is limited. Here, we
examined HCV genetic variation in the full viral protein coding
region to determine if genetic differences in HCV genotype 1 are
associated with the development of HCC or the rate of disease
progression. In sharp contrast to the strong associations we and
others found between viral diversity and covariation patterns with
response to interferon a-based therapy [25–27,30,31], very few
HCV genetic associations were found with development of HCC
or the rate of disease progression.
HCV genetic associations with HCC
The HCC and cirrhotic control sequences were very similar,
but we were able to identify two differences between them. First,
there were 25 positions where the distribution of amino acids in
the HCC and cirrhotic sequences were significantly different,
which was more than the differences observed between control
sequence sets in which these sequences were randomly re-sorted
without regard for disease state. Four of these positions were
within the p7 gene (Table 2). This clustering of differences within
the very small p7 protein (63 residues) may imply a previously
undefined role for this ion channel protein in the progression to
HCC within a badly diseased liver. Three studies from Japan
previously examined the entire HCV ORF for positions of
variability associated with HCC [64,65] [66]. These studies each
identified up to nine positions in the core, E2, NS2, NS3 and
NS5A genes where the amino acid distribution differed signifi-
cantly between viruses from HCC patients and asymptomatic
controls. The positions of skewed amino acid distributions we
found were not the same as the sites found by the Japanese
investigators. Together, these observations indicate that there may
be some sites in the HCV genome where sequence differences are
associated with HCC, but the inconsistency in the positions
identified implies that it is unlikely such differences will be
informative mechanistically or diagnostically. Second, we found
eight positions under positive selection that were unique to either
the HCC or cirrhotic control groups that were not under positive
selection in randomly selected sets of genotype 1b sequences
(Table 3). These positions may therefore be under evolutionary
pressures associated with these advanced disease states.
Nucleotide sequence variations at eleven positions within the
core gene have been previously associated with HCC [54], and
amino acid variations at core positions 70 and 91 are associated
with HCC in HCV 1b-infected patients, especially in Japan [55–
57,66]. However, sequences corresponding to the non-HCC
signature strongly predominated at eight of these eleven nucleotide
positions in both the cirrhotic control sequences and the HCC
sequences. This observation was confirmed by evaluating an
external set of cirrhotic patients [62] Table 5). The three
exceptions were at nucleotides 78, 209 (within codon 70), and
nucleotide 271 (in codon 91). Here, the HCC signature
predominated in both the HCC and cirrhotic sequences. The
previous studies that identified genetic associations in the HCV
core gene with HCC used non-cirrhotic patients as controls
[54,58], but 80–90% of HCV-associated HCCs develop within a
cirrhotic liver [82]. The equal prevalence of the cancer-associated
genetic signatures in the HCC and cirrhotic control sequences
indicates that these signatures are more likely to reflect an
adaptation of HCV to a cirrhotic liver rather than direct
associations with HCC.
We found no significant differences in the covariance networks
between the HCC and cirrhotic controls. This result in is contrast
to our previous covariance network analyses of HCV that
identified strong signatures associated with early response to
interferon-based treatment [27]. Furthermore, a different covari-
Table 7. Positions where the distribution of amino acids differ between the rapid and slow progressor sequences.
Time point 1 Time point 2
Position Protein P value Position Protein P value
308 E1 0.038 308 E1 0.032
333 E1 0.040 391 E2 0.047
453 E2 0.031 464 E2 0.009
464 E2 0.028 853 NS2 0.034
490 E2 0.045 883 NS2 0.040
766 p7 0.038 1655 NS3 0.043
827 NS2 0.045 1723 NS4B 0.032
883 NS2 0.043 1747 NS4B 0.002
1723 NS4B 0.006 2047 NS5A 0.044
1746 NS4B 0.046 2361 NS5A 0.043
1747 NS4B 0.010 2369 NS5A 0.043
2181 NS5A 0.040 2414 NS5A 0.043
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ance algorithm has also identified associations with therapy
outcome, gender and ethnicity of the patient [31]. The success
of these methods when applied to data sets of similar size in finding
associations with response to therapy but not with HCC implies
that there are no strong HCV genome-wide genetic signatures
specifically associated with HCC.
HCV genetic associations with the rate of disease
progression
The only substantial difference we detected between HCV
sequences from the rapid and slow progressors was that the slow
progressors were under greater positive selection than the rapid
progressors (Table 8). The primary driver of positive selection in
HCV is escape from adaptive immune responses [83,84], and
hence this result may reflect a waning of anti-HCV immunity in
the deteriorating hepatic environment. It may also be related to
reduced HCV antigen burden due to reduced HCV replication in
the badly diseased liver tissue. The five other measures of genetic
differences that we evaluated all failed to reveal significant
differences between the rapid and slow progressor sequences at
either of the two time points assessed. This lack of difference
between the sequence sets, which includes the covariance
networks, implies that any potential HCV genetic differences
associated with the rate of disease progression must be smaller
than the statistical power provided by sample sizes of 30 per arm.
This in turn implies that HCV genetic differences are unlikely to
be a dominant cause of differential disease progression in genotype
1a infected patients.
Limitations and strengths and of this study
This study has four notable technical limitations. First, sample
sizes were limited to 22–30 sequences per arm in the comparisons.
This limited the statistical power in these analyses compared to
larger studies that have focused on discrete regions of the HCV
genome [54,57,62,85]. Second, this is a cross-sectional retrospec-
tive study that cannot resolve whether the genetic patterns
associated with HCC helped cause HCC or are viral adaptations
to the neoplastic/cancerous environment. Third, the failure to
identify HCV genetic sequence differences associated with rate of
disease progression may have been partially affected by the fact
that all HALT-C participants had failed prior interferon a plus
ribavirin treatment. We and others have reported that HCV inter-
patient genetic diversity is lowest among non-responders to
interferon-based antiviral therapy [25,26,86]. This may limit the
generality of the conclusions related to rate of disease progression.
Finally, the HCV sequences were obtained from serum rather
than from liver biopsies because liver samples were not available.
The large majority of HCV in circulation is derived from
hepatocytes, but differential genetic variability in core sequences
from tumor tissue compared to core sequences from non-tumorous
tissue has been demonstrated for some patients [87,88].
This study has three strengths that permit substantial conclu-
sions to be drawn despite the overall negative nature of the data.
First, we employed two carefully selected sample sets derived from
patients who had been matched with regard to HCV subtype, age,
gender, and possible confounders of liver disease development in
order to isolate effects on liver pathology associated with viral
genetic variation within HCV genotype 1. Second, the study
provided a comprehensive evaluation of HCV’s coding potential
that was not blind to amino acid variations outside of a pre-
determined target region. Third, we previously found strong
genetic diversity differences between responders and non-respond-
ers to pegylated interferon a plus ribavirin therapy using these
same methods on data sets of similar size that were derived from
the Virahep-C study [25–27,79]. For example, with samples sizes
of 23–24 sequences per arm, we identified amino acid diversity
differences in the core, NS3, and NS5A genes at p#0.005 between
early responders and non-responders to interferon-based treat-
ment [26]. Therefore these methods can identify biologically
significant viral genetic differences. This indicates that if viral
genetic diversity differences existed between the HCC and control
sequences or between the rapid and slow progressors, they must be
substantially smaller than the viral genetic differences associated
with response to interferon-based therapy.
Concluding comments
The primary implications of this work stem from the contrast of
the negative results from both of the pathology-related sequence
data sets to the positive results from similar efforts focused on
response to interferon-based therapy. This contrast implies that
the differential rate of disease progression and HCC development
among HCV patients is not strongly influenced by variability in
HCV’s intrinsic ability to control the type 1 interferon response. It
also implies that rapid disease progression and HCC do not have a
large and/or consistent impact on HCV’s genetic patterns.
Together, the lack of strong HCV genetic differences between
HCC and cirrhotic patients and between rapid and slow disease
progressors implies that host and/or environmental factors are the
dominant causes of differential disease presentation in HCV
patients.
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